ReNetX Bio reports that the FDA has has allowed the Company’s Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204.
Axonal loss is a common, yet unaddressed pathology, in a broad range of chronic and acute diseases of the central and ocular nervous systems. The Company’s technology relies on blocking inhibitory proteins to promote regrowth of neurons and was developed by ReNetX Founder and Scientific Advisor Stephen Strittmatter, MD, PhD, Vincent Coates Professor of Neurology at Yale.